Paravertebral injection of botulinum toxin-A reduces lumbar vertebral bone quality.

Aging has been associated with decreases in muscle strength and bone quality. In older patients, paravertebral muscle atrophy tends to coincide with vertebral osteoporosis. The purpose of this study was to investigate the effects of a paravertebral injection of botulinum toxin-A (BTX) on paravertebral muscle atrophy and lumbar vertebral bone quality. Forty 16-week-old female SD rats were randomly divided into four groups: (1) a control group (CNT); (2) a resection of erector spinae muscles group (RESM); (3) a botulinum toxin-A group (BTX), treated with 5U BTX by local injection into the paravertebral muscles bilaterally; and (4) a positive control group (OVX), treated by bilateral ovariectomy. Rats were sacrificed at 12 weeks post-surgery, and the lumbar vertebrae (L3-L6) were collected. Micro-CT scans showed that rats in the three experimental groups-particularly the OVX rats-had fewer trabeculae and trabecular connections than rats in the CNT group. BMD was significantly lower in rats in the OVX, RESM, and BTX groups than in the CNT group (p < 0.01). Vertebral compression testing revealed significantly lower maximum load, energy absorption, maximum stress, and elastic modulus values in the three experimental groups compared with the CNT group (p < 0.01); these parameters were lowest in the OVX group (p < 0.05). Our results demonstrate that local BTX injection causes sufficient muscle atrophy and dysfunction to result in local lumbar vertebral bone loss and quality deterioration in a model of paravertebral muscle atrophy. Clinical Significance: The muscular tissues surrounding the lumbar vertebrae should be preserved during clinical surgery to avoid loss of bone quality and mass in the adjacent bone. Maintaining paravertebral muscle strength is an important consideration for patients with early osteoporosis.